1,649 results match your criteria: "Pruritus and Systemic Disease"
Dupilumab, corticosteroids and their combination for the treatment of bullous pemphigoid.
An Bras Dermatol
December 2024
Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing, China. Electronic address:
Background: Conventional systemic corticosteroid therapy for bullous pemphigoid (BP) has been challenged due to severe adverse events. Dupilumab has emerged as an alternative therapeutical option of BP patients.
Objectives: To evaluate the efficacy of dupilumab monotherapy and the combination with medium/low-dose corticosteroids for BP treatment.
Tralokinumab Treatment in Adult Atopic Dermatitis Patients: 28-Week Evaluation of Clinical Effectiveness, Safety, Serum Proteins and Total IgE Levels.
Allergy
December 2024
National Expertise Center for Atopic Dermatitis, Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, The Netherlands.
Introduction And Objectives: Tralokinumab-a biological that specifically targets interleukin-13-is one of the newer advanced systemic treatments for patients with moderate-to-severe atopic dermatitis (AD). Although safety and efficacy have been shown in phase-III clinical trials, daily practice data are needed. Therefore, the aim of this study was to evaluate 28-week safety and effectiveness, serum proteins and total IgE levels in adult AD patients treated with tralokinumab in daily practice.
View Article and Find Full Text PDFPractical guide for the diagnosis and treatment of localized and generalized cutaneous pruritus (chronic itch with no underlying pruritic dermatosis).
J Dermatol
December 2024
Department of Dermatology, National Defense Medical College, Tokorozawa, Japan.
Itch, also known as pruritus, is one of the most prevalent symptoms observed in dermatological practices. Itch frequently arises from primary pruritic dermatoses, although it may also manifest in the absence of a primary pruritic skin rash. The latter itchy condition is referred to as "cutaneous pruritus" in the Japanese guidelines published in 2020.
View Article and Find Full Text PDFOccupational anaphylaxis: A Position Paper of the German Society of Allergology and Clinical Immunology (DGAKI).
Allergol Select
November 2024
Department of Dermatology and Allergy Biederstein, School of Medicine and Health, Technical University of Munich TUM).
Background: Anaphylaxis is a systemic allergic reaction that is potentially life-threatening. Occupational anaphylaxis is an anaphylaxis that occurs in an occupational context. In this position paper, we propose diagnostic criteria for occupational anaphylaxis and provide an overview of the current state of knowledge in terms of prevalence, triggers, prevention, and management.
View Article and Find Full Text PDFAtopic dermatitis.
Allergy Asthma Clin Immunol
December 2024
Division of Allergy, IWK Health Centre, Department of Pediatrics, Dalhousie University, Halifax, Nova Scotia, Canada.
Atopic dermatitis (AD) is a common, chronic skin disorder that can significantly impact the quality of life (QoL) of affected individuals as well as their families. Although the pathogenesis of the disorder is not yet completely understood, it appears to result from the complex interplay between defects in skin barrier function, environmental and infectious agents, and immune dysregulation. There are no diagnostic tests for AD; therefore, the diagnosis is based on specific clinical criteria that take into account the patient's history and clinical manifestations.
View Article and Find Full Text PDFElevated C-reactive protein levels and cardiovascular risk in prurigo nodularis patients with sleep disturbance: a multi-center cohort study.
Arch Dermatol Res
December 2024
Department of Dermatology, University of Maryland School of Medicine, 419 West Redwood Street, Baltimore, MD, 21201, USA.
Patients with prurigo nodularis (PN) present with pruritus which may lead to sleep disturbances and systemic comorbidities. The objective of our study was to determine the risk of sleep disorders in PN and its association with systemic inflammation and adverse cardiovascular outcomes. We conducted a retrospective population-level cohort using a global health records database to analyze the development of sleep disorders, C-reactive protein (CRP) levels, and risk of cardiovascular disease and mortality in PN compared to controls.
View Article and Find Full Text PDFEfficacy of Plant Extract-Based Solutions Compared to Chlorhexidine and Miconazole Shampoo for the Treatment of Superficial Pyoderma in Dogs.
Vet Med Sci
January 2025
Centro Universitario UAEM Amecameca, Universidad Autónoma del Estado de México, Amecameca de Juárez, Estado de México, México.
Article Synopsis
- Canine superficial pyoderma (CSP) is a prevalent skin condition in dogs, and there's growing concern over antibiotic resistance, making natural remedies an appealing option.
- This study compares the effectiveness of natural topicals containing essential oils and plant extracts against a standard medicated shampoo with chlorhexidine and miconazole for treating CSP in thirty dogs.
- Results indicated that natural topicals significantly reduced skin lesions, pruritus, and bacterial counts more effectively than the medicated shampoo, suggesting they could be used alongside traditional treatments for CSP.
Immunoglobulin G4-related pancreatitis presenting as an obstructive pancreatic mass in a Latino male.
J Family Community Med
October 2024
Department of Family Medicine, Texas Tech University Health Sciences Center, Transmountain Campus, El Paso, TX, USA.
Article Synopsis
- IgG4-related disease (IgG4-RD) is an autoimmune condition that can affect various organs, but there is limited research on its occurrence in Latino populations.
- The case report discusses a 40-year-old Latino male diagnosed with IgG4-related pancreatitis, presenting symptoms like diarrhea, jaundice, and elevated liver enzymes.
- After undergoing a biopsy which ruled out cancer, the patient received glucocorticoid therapy that improved his symptoms and liver function, with no negative effects from a COVID-19 infection during treatment.
CHILDHOOD LICHEN PLANUS: A STUDY OF 54 CASES FROM PAKISTAN.
J Ayub Med Coll Abbottabad
November 2024
Combined Military Hospital, Bahawalpur-Pakistan.
Article Synopsis
- A cross-sectional study was conducted in Pakistan to analyze the clinical characteristics of Childhood Lichen Planus (LP) in patients under 15 years of age at a Tertiary Care Hospital from December 2021 to December 2023.
- The study found that the average age of onset was approximately 9.8 years, with 94.4% of patients experiencing pruritus; classic LP was the most common type identified.
- The research concluded that childhood LP is rare, closely resembles adult LP, and shows no significant gender preference, with instances of nail and mucosal involvement being particularly uncommon.
[Atypical and/or systemic dermatologic disorders related to immune checkpoint inhibitors: A review].
Rev Med Interne
November 2024
Service de médecine interne et immuno-pathologie, IUCT - Oncopôle, CHU de Toulouse, 1, avenue Joliot-Curie, 31100 Toulouse, France.
Article Synopsis
- Immunological checkpoint inhibitors, used in treating various cancers, can cause toxic side effects, particularly dermatological disorders.
- Common skin issues like maculopapular erythema and pruritus often occur, but rarer conditions such as fasciitis and scleroderma can also arise.
- Recognizing these unusual manifestations is crucial for internists, as they may mimic other diseases or paraneoplastic syndromes, requiring specific diagnostic and treatment approaches related to ICI toxicity.
Systemic treatment of recessive dystrophic epidermolysis bullosa with mesenchymal stromal cells: a scoping review of the literature and conclusions for future clinical research.
J Dermatolog Treat
December 2024
RHEACELL GmbH & Co. KG, Heidelberg, Germany.
Article Synopsis
- - Mesenchymal stromal cells (MSCs) show promise as a treatment for recessive dystrophic epidermolysis bullosa (RDEB), potentially aiding in tissue repair and improving collagen VII at the skin layer junction.
- - A review of clinical research from PubMed revealed that six early-phase studies and one case report involved 59 patients receiving MSC infusions, with only a few mild adverse events and overall positive feedback on skin improvements and quality of life.
- - While the evidence is still limited due to the challenges of studying rare diseases, the results suggest MSC therapy could benefit RDEB patients, warranting further investigation into this treatment method.
Innovations in Cutaneous Lupus.
Dermatol Clin
January 2025
Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, 1120 Northwest 14th Street, Suite 9, Miami, FL 33136, USA.
Article Synopsis
- Cutaneous lupus erythematosus (CLE) is a skin condition caused by an autoimmune response, part of the broader lupus family.* -
- Current treatments, including systemic immunosuppressants and topical options, often provide only moderate relief for symptoms like itching and skin discoloration, leaving patients with unmet needs.* -
- Recent advancements in biologics and other systemic medications have improved options for dermatologists and rheumatologists in managing CLE effectively.*
Unveiling the Impact of Moderate and Severe Atopic Dermatitis: Insights on Burden, Clinical Characteristics, and Healthcare Resource Utilization in Adult Greek Patients from the APOLO Cross-Sectional Study.
J Clin Med
October 2024
Pfizer Hellas SA, 15451 Neo Psichiko, Greece.
Article Synopsis
- * A study in Greece involved 184 adults, revealing that many suffer from additional issues like obesity and allergic comorbidities, with the majority receiving specific treatment for their condition.
- * Key findings included high rates of pain, severe itching, and sleep disturbances, with patients reporting substantial reductions in work productivity and overall well-being.
Approach to skin problems in travellers: clinical and epidemiological clues.
J Travel Med
December 2024
Infectious and Tropical Diseases, Sorbonne University, Faculté de médecine, Hôpitaux Universitaires Pitié Salpêtrière, Boulevard de l'Hôpital, 75013, Paris, France.
Article Synopsis
- Travelers often experience skin problems requiring medical attention, with proper diagnosis relying on clinical examinations and understanding travel history and behaviors.* -
- The most common travel-related skin issues include insect bites, sunburns, and infections like hookworm and bacteria, with specific diseases like dengue fever and schistosomiasis being noteworthy.* -
- Evaluating skin conditions involves considering travel history, activities, and specific lesion characteristics, which help identify risks and guide treatment.*
PD-1 inhibitor sintilimab treated patients with metastatic triple-negative breast cancer.
Front Cell Dev Biol
October 2024
Department of Breast Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Article Synopsis
- Triple-negative breast cancer (TNBC) poses significant treatment challenges, and this study aimed to evaluate the safety and effectiveness of the PD-1 inhibitor sintilimab in patients with metastatic TNBC using real-world data.
- A total of 40 patients (average age of 55.5) were treated with sintilimab, showing a median response duration of 2.8 months and an overall response rate of 22.5%, with median progression-free survival (PFS) of 3.5 months.
- Side effects were generally manageable; common issues included fatigue and skin rash, with a few severe cases noted, and 40% of patients had PD-L1-positive tumors, suggesting potential for enhanced treatment efficacy.
Efficacy and Safety of Upadacitinib vs Dupilumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: Week 16 results of an Open-label, Randomized, Efficacy Assessor-Blinded Head-to-Head Phase 3b/4 Study (Level Up).
Br J Dermatol
October 2024
Department of Dermatology and Venerology, Medical Center, University of Freiburg, Germany.
Article Synopsis
- * The study compared the effectiveness and safety of upadacitinib (UPA) and dupilumab (DUPI) in adolescents and adults with moderate-to-severe AD over 16 weeks, with UPA showing better results in reducing skin severity and itching.
- * UPA was found to be significantly more effective than DUPI in achieving the treatment goals, with no new safety concerns reported during the study.
Assessing Disease Control in Patients with Atopic Dermatitis by Using the Atopic Dermatitis Control Tool in Daily Practice.
Dermatology
December 2024
Department of Dermatology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Article Synopsis
- Atopic dermatitis (AD) significantly impacts patients' quality of life, and the Atopic Dermatitis Control Tool (ADCT) is used to measure how well it's being managed in adults.
- A study involving 863 participants revealed that 59% had controlled AD, while those with uncontrolled AD had higher symptom severity and were more likely to be using topical treatments only.
- The findings suggest that shifting treatment strategies from topical to systemic therapies might benefit patients struggling with uncontrolled AD symptoms.
Real-world burden of atopic dermatitis: Austrian and Swiss data from the MEASURE-AD study.
J Dermatolog Treat
December 2024
Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
Article Synopsis
- Atopic dermatitis (AD) causes significant skin issues and itching, greatly affecting people's quality of life, yet many treatment needs remain unmet.
- A study involving 98 patients from Austria and Switzerland highlighted that most had moderate to severe AD and experienced issues like pruritus and multiple flares, with many reporting negative effects on sleep and mental health.
- The findings emphasize the ongoing challenges in AD management, including delays in diagnosis and the need for more effective therapies to enhance patient well-being.*
Real-World Evaluation of the Effectiveness and Safety of Dupilumab in Bullous Pemphigoid: An Ambispective Multicenter Case Series.
Br J Dermatol
October 2024
Department of Dermatology. Hospital del Mar Research Institute. Barcelona, Spain. Universitat Pompeu Fabra (UPF). Barcelona, Spain.
Article Synopsis
- - A study evaluated the effectiveness and safety of dupilumab for treating bullous pemphigoid in elderly patients, with a focus on those who typically have other health issues that make standard treatments unsuitable.
- - The results showed that 53.4% of patients achieved complete remission within 4 weeks and 95.7% by week 52, with a significant reduction in itchiness and a dramatic decrease in the need for corticosteroids.
- - The treatment was found to be safe, with most adverse events being mild, and factors like shorter disease duration and exclusive skin involvement were linked to better treatment responses.
Systemic Therapy for Atopic Dermatitis in Children and Adolescents: A US Expert Consensus.
Dermatology
December 2024
Departments of Dermatology and Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Article Synopsis
- * Mild-to-moderate AD is typically treated with topical anti-inflammatory medications and basic skin care, while moderate-to-severe cases often need systemic therapy, including off-label immunosuppressants, which carry safety concerns.
- * New targeted biologics and small molecules are emerging as more effective and safer treatment options for AD, leading to the development of standardized recommendations for treating pediatric patients with moderate-to-severe cases.
Anti-inflammatory Capacity of a Medicinal herb extract, , on and models-induced atopic dermatitis.
Heliyon
October 2024
Department of Integrated Drug Development and Natural Products, Graduate School, Kyung Hee University, Seoul, 02447, Republic of Korea.
Article Synopsis
- Bunge (AA), a plant from the Liliaceae family, has traditional uses for managing inflammation, but its effects on atopic dermatitis (AD) were previously unexplored.
- The study showed that topical AA ointment significantly reduced AD symptoms in mice and keratinocytes by improving skin conditions and reducing inflammation markers.
- AA works by lowering levels of certain cytokines and signaling molecules involved in skin inflammation, suggesting it could be a promising treatment for atopic dermatitis.
Rapid identification of primary atopic disorders (PAD) by a clinical landmark-guided, upfront use of genomic sequencing.
Allergol Select
October 2024
Center for Child and Adolescent Health, Helios Hospital Krefeld, Academic Hospital of RWTH Aachen, Krefeld.
Article Synopsis
- Primary atopic disorders (PAD) are rare genetic conditions caused by specific gene variants that affect skin and immune function, making diagnosis challenging among common allergic disease cases.
- Identifying PAD requires recognizing clinical red flags like family history and unusual infections, as conventional lab tests are inadequate for definitive diagnosis.
- Whole-genome sequencing (WGS) enhances diagnostic efficiency and accuracy, but requires careful interpretation and collaboration among specialists to effectively manage PAD cases.
Article Synopsis
- The study aimed to compare the skin adhesion of a new rotigotine transdermal patch (ROT-TDS) to an existing product for patients with Parkinson's disease (PD).
- Research included pharmacokinetic testing on healthy adults and a trial on PD patients to assess adhesion and safety.
- Results showed that ROT-TDS had similar effectiveness and safety as the reference patch but also demonstrated better skin adhesion, with a higher percentage of patches staying adhered through the dosing period.
Emerging Biologic Therapies for the Treatment of Atopic Dermatitis.
Drugs
November 2024
Department of Dermatology, Unidade Local de Saúde de Santo António, Porto, Portugal.
Article Synopsis
- - Atopic dermatitis (AD) is a common inflammatory skin condition that significantly affects patients' quality of life, with traditional treatments often having limited effectiveness and safety issues.
- - New biologic therapies aim to specifically target immune pathways involved in AD, including various interleukins and the OX40-OX40L axis, offering potential improvements in treatment efficacy and safety compared to conventional methods.
- - Emerging treatments, such as bispecific antibodies and thymic stromal lymphopoietin inhibitors, show promise in managing AD symptoms, but further long-term studies are needed to validate their effectiveness and safety in real-world settings.
Cannabis-Containing Cream for CKD-Associated Pruritus: A Double-Blind, Placebo Controlled Trial.
Kidney Med
October 2024
Department of Internal Medicine, Faculty of Medicine, Thammasat University, Rangsit, Pathum Thani, Thailand.
Article Synopsis
- This study compares the effectiveness of cannabis cream versus a placebo for relieving itching in patients with chronic kidney disease (CKD) undergoing hemodialysis.
- Conducted as a double-blind randomized controlled trial with 60 participants, the primary measure of success was the itching intensity score (WI-NRS) after 4 weeks.
- Results showed a significant reduction in itching for the cannabis group compared to placebo at 4 weeks, but the study's small sample size and other limitations make it difficult to draw broad conclusions.